Follow us on our mission to treat fibrosis and restore organ function in multiple therapeutic areas
Agomab Announces Positive Topline Phase 2a Interim Results for AGMB-129 in Fibrostenosing Crohn’s Disease
Antwerp, Belgium, March 10, 2025
–AGMB-129 hit all primary and secondary endpoints in interim read-out from 44 patients after 12 weeks treatment
–Detailed interim STENOVA results to be presented at future scientific conference
–STENOVA clinical trial on track to report full results in the fourth quarter of 2025
–Open-label extension study initiated
Agomab Therapeutics NV (‘Agomab’) today announced positive interim results from 44 patients completing treatment in the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (TGFβ-RI or ALK5) for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD).
Agomab Announces the Appointment of Former Sandoz CFO Colin Bond to its Board of Directors
Antwerp, Belgium, November 18, 2024
Agomab Therapeutics NV (‘Agomab’) today announced the appointment of Colin Bond to the company’s Board of Directors as a non-executive Director and Chairman of the Audit Committee. With an extensive career in finance that spans over three decades at leading international corporations, Colin also brings fifteen years of experience as a CFO at listed biopharmaceutical companies in Switzerland, Germany and the US
Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis- focused Pipeline
Antwerp, Belgium, October 25, 2024
Agomab Therapeutics NV (‘Agomab’) today announced a $89 million (€82.1 million) Series D financing round, with participation from new investors Sanofi and Invus,as well as existing investors.
The proceeds from the Series D will be used to further advance the ongoing clinical development of Agomab’s lead candidate, AGMB-129, a gut-restricted oral small molecule inhibitor of ALK5 (TGFβ1R), in patients with fibrostenosing Crohn’s disease (FSCD). Interim data from the Phase 2a STENOVA trial are expected in the first quarter of 2025. In addition, proceeds will be used to advance the clinical
development for AGMB-447, a lung-restricted inhaled small molecule inhibitor of ALK5, that is currently in a Phase 1 clinical trial in healthy subjects and patients with idiopathic pulmonary fibrosis (IPF), as well as initial clinical development of AGMB-101, a full MET agonistic antibody currently in the final stages of IND-enabling studies, which the company intends to develop for liver cirrhosis.
“WE ARE DETERMINED TO IMPROVE THE LIVES OF PATIENTS WITH FIBROTIC DISEASES. WE ARE BUILDING A LEADING COMPANY THAT COMBINES TRANSFORMATIVE SCIENCE WITH THE COMMITMENT AND PASSION OF OUR EXPERIENCED TEAM, PARTNERS, AND INVESTORS.”
Tim Knotnerus, Chief Executive Officer
